<DOC>
	<DOC>NCT00115427</DOC>
	<brief_summary>This randomized study was designed to evaluate the efficacy and safety of IPu-infused liatermin (15mg/putamen/day) compared with placebo in subjects with symptomatic, levodopa-response Parkinson's disease. This study consisted of a 90-day evaluation period followed by implantation of the IPu delivery system and then a 6-month double-blind treatment period.</brief_summary>
	<brief_title>Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Diagnosis of bilateral, idiopathic Parkinson's disease</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Bilateral, Idiopathic Parkinson's Disease</keyword>
</DOC>